transplant rejection

(redirected from Acute transplant rejection)
Also found in: Wikipedia.

transplant rejection

Graft rejection, organ rejection, tissue rejection Immunology The constellation of host immune responses evoked when an allograft tissue is transplanted into a recipient; rejection phenomena may be minimized by optimal matching of MHC antigens and ABO blood groups and ameliorated with immunosuppressants–eg, cyclosporin, tacrolimus, rapamycin Exceptions of TR Corneal transplants, identical twins. See Graft-versus-host disease, HLA, MHC, Tissue typing.

transplant

1. an organ or tissue taken from the body and grafted into another area of the same individual or another individual.
2. to transfer tissue from one part to another or from one individual to another.

ovum transplant
see ovum transplant.
transplant rejection
References in periodicals archive ?
Columbia, MD, announced that an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using its proprietary ImmuKnow immune cell function test was found to identify patients that may be at risk for early acute transplant rejection and unstable kidney function in the first three months following transplantation.
Cylex says a statistically significant correlation was reported between high pre-transplant levels of cellular immune response, as measured using ImmuKnow immune cell function test, and early acute transplant rejection as well as unstable kidney function within the first 90 days following kidney transplantation.
today announced the publication of an independent, peer reviewed, clinical research study in which the level of cellular immune response measured prior to kidney transplantation using the Company's proprietary ImmuKnow(R) immune cell function test was found to identify patients that may be at risk for early acute transplant rejection and unstable kidney function in the first three months following transplantation.
The primary clinical endpoint is defined as the occurrence of acute transplant rejection, graft loss, or death within 6 months post-transplant.
ABX-CBL has been tested in various acute transplant rejection indications in over 50 patients to date.
Acute transplant rejection occurs when cells of the immune system recognize the transplanted organ as foreign and attack it as a potential threat.
A phase I/II study of BTI-322 for the treatment of acute transplant rejection is currently underway at the Massachusetts General Hospital (MGH) under an Investigational New Drug (IND) application submitted by BioTransplant.
The Phase I/II study is designed to assess the tolerability and potential efficacy of BTI-322 in kidney transplant patients experiencing their first episode of biopsy-proven, acute transplant rejection.
Donor kidney pre-treatment with Anti-CD45 may substantially reduce the dangers and added health-care costs associated with treating an acute transplant rejection response.
Donor kidney pre-treatment with LM-CD45 may substantially reduce the dangers and added healthcare costs associated with the treating an acute transplant rejection response.
This treatment appeared to diminish the frequency of acute transplant rejection but elicited a human anti-mouse antibody (HAMA) immune response that restricted treatment to a two-week period.
We also expanded clinical trials of Oncolysin S, for the treatment of small-cell lung cancer, into Europe, and filed with the Food and Drug Administration to begin human testing of Oncolysin CD6, for the prevention of acute transplant rejection.

Full browser ?